MET and non-small cell lung carcinoma: NSCLC can acquire drug resistance through a secondary mutation of exon 20 of EGFR gene (T790M) and the amplification of c‐MET gene; additionally, Axl has been recently found to correlate with the acquired drug resistance of EGFR‐TKI,5, 6 but the molecular mechanism of Axl leading to EGFR‐TKI resistance in NSCLC lung cancer cells is not fully understood.